|
|
xix | |
Foreword |
|
xxiii | |
|
Chapter 1 Nanotherapeutics and Nanobiotechnology |
|
|
1 | (14) |
|
|
|
1 | (1) |
|
|
1 | (2) |
|
|
3 | (1) |
|
4 Applications of Nanobiotechnology |
|
|
4 | (1) |
|
5 Toxicity of the Nanocarrier Systems |
|
|
5 | (1) |
|
|
5 | (1) |
|
7 Challenges for Nanobiotechnology |
|
|
5 | (1) |
|
8 Ethical Perspective of Nanobiotechnology |
|
|
6 | (3) |
|
9 Regulatory Perspective of Nanobiotechnology |
|
|
9 | (1) |
|
|
9 | (1) |
|
|
10 | (5) |
|
|
10 | (5) |
|
Chapter 2 Application and Perspective of pH-Responsive Nano Drug Delivery Systems |
|
|
15 | (20) |
|
|
|
|
|
|
15 | (6) |
|
2 Polymer-Drug Conjugates |
|
|
21 | (1) |
|
|
21 | (3) |
|
|
24 | (1) |
|
|
25 | (2) |
|
|
27 | (1) |
|
|
27 | (2) |
|
8 Miscellaneous Nanocarriers |
|
|
29 | (1) |
|
|
29 | (6) |
|
|
29 | (6) |
|
Chapter 3 Mechanism for Development of Nanobased Drug Delivery System |
|
|
35 | (34) |
|
|
|
|
|
35 | (8) |
|
1.1 Nanomaterials in Drug Delivery |
|
|
36 | (7) |
|
2 Mechanisms for Synthesis of Nanobased Drug Delivery System |
|
|
43 | (7) |
|
2.1 Thin Film Hydration Method |
|
|
43 | (1) |
|
2.2 Solvent Evaporation Method |
|
|
43 | (1) |
|
2.3 Emulsions- Diffusion Method |
|
|
43 | (1) |
|
2.4 Double Emulsion and Evaporation Method |
|
|
44 | (1) |
|
2.5 Solvent Displacement/Precipitation Method |
|
|
44 | (1) |
|
|
45 | (1) |
|
2.7 Emulsion Polymerization Technique |
|
|
45 | (1) |
|
2.8 Mini-Emulsion Polymerization |
|
|
46 | (1) |
|
2.9 Microemulsion Polymerization |
|
|
46 | (1) |
|
2.10 Interfacial Polymerization |
|
|
47 | (1) |
|
2.11 Controlled/Living Radical Polymerization |
|
|
47 | (1) |
|
|
48 | (1) |
|
2.13 Solvent Injection Method |
|
|
48 | (1) |
|
2.14 Supercritical Fluid Technology |
|
|
49 | (1) |
|
2.15 Methods for Synthesis of Dendrimers |
|
|
50 | (1) |
|
3 Mechanism of Drug Targeting |
|
|
50 | (2) |
|
|
50 | (1) |
|
|
51 | (1) |
|
|
52 | (17) |
|
|
52 | (17) |
|
Chapter 4 Nanobased Nano Drug Delivery: A Comprehensive Review |
|
|
69 | (24) |
|
|
|
59 | (10) |
|
2 How to Design Nanobased Drug Delivery |
|
|
69 | (2) |
|
3 Route of Administration for Nanobased Drug Delivery |
|
|
71 | (1) |
|
4 Types of Nano Drug Delivery Systems |
|
|
71 | (11) |
|
|
72 | (2) |
|
|
74 | (1) |
|
|
75 | (3) |
|
|
78 | (2) |
|
|
80 | (1) |
|
4.6 Magnetic Nanoparticles |
|
|
81 | (1) |
|
5 Characterization of Nano Drug Delivery System |
|
|
82 | (1) |
|
6 Advantages of Nano Drug Delivery System |
|
|
82 | (2) |
|
7 Disadvantages of Nano Drug Delivery System |
|
|
84 | (1) |
|
8 Recent Patents in Nano Drug Delivery |
|
|
84 | (4) |
|
9 Concluding Remarks and Future Prospects for Nano Drug Delivery |
|
|
88 | (5) |
|
|
88 | (5) |
|
Chapter 5 Recent Advances in Development of Nano Drug Delivery |
|
|
93 | (40) |
|
|
|
|
93 | (6) |
|
2 Recent Advances in Nano Drug Delivery |
|
|
99 | (15) |
|
2.1 Lipid-Based Nano Drug Delivery Systems |
|
|
99 | (4) |
|
2.2 Polymeric Nano Drug Delivery Systems |
|
|
103 | (4) |
|
2.3 Silica-Based Nano Drug Delivery Systems |
|
|
107 | (3) |
|
2.4 Carbon-Based Nano Drug Delivery Systems |
|
|
110 | (1) |
|
2.5 Metal-Based Nano Drug Delivery Systems |
|
|
111 | (3) |
|
3 Nanoformulations: FDA Approved and in Recent Clinical Trials |
|
|
114 | (1) |
|
4 Challenges of Nano Drug Delivery |
|
|
114 | (9) |
|
|
123 | (1) |
|
6 Commercially Available Nano Drug Delivery Systems |
|
|
123 | (3) |
|
7 Conclusions and Future Perspectives |
|
|
126 | (7) |
|
|
126 | (7) |
|
Chapter 6 Thermoresponsive Drug Delivery Systems, Characterization and Application |
|
|
133 | (24) |
|
|
|
|
133 | (1) |
|
|
134 | (2) |
|
|
134 | (2) |
|
2.2 Glass Transition Temperature |
|
|
136 | (1) |
|
3 Thermoresponsive Polymers |
|
|
136 | (4) |
|
3.1 Poly(N-Isopropylacrylamide) and Derivatives |
|
|
137 | (2) |
|
3.2 Poly(N-Vinylisobutyramide) and Derivatives |
|
|
139 | (1) |
|
3.3 Poly(Oxyethylene Vinyl Ether) |
|
|
139 | (1) |
|
3.4 Cellulose Derivatives |
|
|
140 | (1) |
|
4 Delivery Systems and Applications |
|
|
140 | (10) |
|
|
141 | (1) |
|
|
142 | (2) |
|
4.3 Polymeric Nanoparticles |
|
|
144 | (1) |
|
|
145 | (1) |
|
|
146 | (1) |
|
4.6 Elastin-Like Peptide-Drug Conjugates |
|
|
147 | (3) |
|
5 Conclusions and Future Perspectives |
|
|
150 | (7) |
|
|
151 | (6) |
|
Chapter 7 Graphene and Graphene-Based Nanomaterials Are Suitable Vehicles for Drug Delivery |
|
|
157 | (34) |
|
|
|
157 | (1) |
|
2 Structural Aspects of Graphene and Graphene-Based Materials and Their Functionality |
|
|
158 | (2) |
|
3 Physicochemical Aspects of Graphene and Graphene-Based Materials and Their Functionality |
|
|
160 | (1) |
|
4 Broad Classification and Its Functionality |
|
|
161 | (3) |
|
5 Biocompatibility of Graphene and Graphene-Based Materials in Biosystem |
|
|
164 | (5) |
|
6 Factors Affecting Dispersibility of Graphene and Graphene-Based Materials |
|
|
169 | (2) |
|
7 Interactions Between Graphene, Graphene-Based Materials, and Cell/Cell Membrane |
|
|
171 | (5) |
|
8 Modifications to be Brought in Graphene and Graphene Based Materials to Enable Them to be Used as Drug Carriers |
|
|
176 | (5) |
|
|
181 | (10) |
|
|
182 | (1) |
|
|
182 | (9) |
|
Chapter 8 Combination Strategies for Targeted Delivery of Nanoparticles for Cancer Therapy |
|
|
191 | (30) |
|
|
|
|
|
|
|
|
191 | (1) |
|
2 Drug Delivery and Therapeutic Nanovectors |
|
|
192 | (9) |
|
|
193 | (3) |
|
2.2 Nanogels and Polymeric Nanoparticles |
|
|
196 | (1) |
|
2.3 Metal-Based Nanovectors |
|
|
197 | (2) |
|
2.4 Silicon and Silica Nanoparticles |
|
|
199 | (1) |
|
|
200 | (1) |
|
|
201 | (4) |
|
|
201 | (2) |
|
|
203 | (1) |
|
|
204 | (1) |
|
|
205 | (16) |
|
|
206 | (15) |
|
Chapter 9 Nanotechnology Toward Treating Cancer: A Comprehensive Review |
|
|
221 | (36) |
|
|
|
221 | (1) |
|
2 Nanocarriers for Drug Delivery |
|
|
222 | (2) |
|
|
224 | (1) |
|
4 Passive and Active Targeting Strategies |
|
|
225 | (1) |
|
|
225 | (1) |
|
4.2 Aiming at a Target: Active Drug Targeting |
|
|
225 | (1) |
|
5 Multiple Drug Resistance |
|
|
226 | (1) |
|
6 Examples of Nanomedicines for Cancer Approved by FDA and Those Undergoing Clinical Trials |
|
|
227 | (7) |
|
6.1 Doxil (Liposomal Doxorubicin) |
|
|
227 | (4) |
|
|
231 | (1) |
|
6.3 DaunoXome (Liposomal Daunorubicin) |
|
|
232 | (2) |
|
7 Liposomal Daunorubicin and Cytarabine Combination (VYXEOS) |
|
|
234 | (1) |
|
8 Abraxane (Albumin-Bound Paclitaxel, Paclitaxel Protein Bound) |
|
|
234 | (3) |
|
|
237 | (1) |
|
9.1 Lipoplatin (Liposomal Cisplatin) |
|
|
237 | (1) |
|
10 Liposomal Vincristine (Marqibo, OncoTCS) |
|
|
238 | (1) |
|
|
239 | (2) |
|
11.1 Liposomal Cytarabine (DepoCyt) |
|
|
240 | (1) |
|
|
241 | (4) |
|
12.1 Oncaspar (Asparaginase) |
|
|
242 | (1) |
|
|
243 | (2) |
|
|
245 | (1) |
|
|
246 | (1) |
|
15 Mepact (Liposomal Mifamurtide) |
|
|
247 | (1) |
|
16 Ceramide Delivery via Nanoliposomes |
|
|
248 | (1) |
|
|
248 | (9) |
|
|
249 | (7) |
|
|
256 | (1) |
|
Chapter 10 Nanoparticles as Delivery Systems in Cancer Therapy: Focus on Gold Nanoparticles and Drugs |
|
|
257 | (40) |
|
|
|
|
|
257 | (1) |
|
|
258 | (9) |
|
2.1 Polymer-Based Nanoparticles |
|
|
258 | (4) |
|
|
262 | (1) |
|
2.3 Lipid-Based Nanoparticles |
|
|
262 | (2) |
|
2.4 Protein Nanoparticles |
|
|
264 | (1) |
|
2.5 Inorganic Nanoparticles |
|
|
264 | (3) |
|
3 AuNPs in Biology and Medicine |
|
|
267 | (12) |
|
3.1 Biocompatibility and Biodistribution |
|
|
267 | (1) |
|
3.2 Applications of AuNPs (Single Systems) |
|
|
268 | (6) |
|
3.3 Applications of AuNPs (Combined Systems) |
|
|
274 | (5) |
|
4 How Far From Clinical Translation? |
|
|
279 | (1) |
|
|
280 | (17) |
|
|
281 | (1) |
|
|
281 | (14) |
|
|
295 | (2) |
|
Chapter 11 Trends in Nanotechnology for Practical Applications |
|
|
297 | (30) |
|
|
|
|
|
297 | (1) |
|
2 Nanoparticulate Drug Delivery System |
|
|
298 | (1) |
|
3 Advantages of Nanoparticulate Drug-Delivery Systems |
|
|
299 | (1) |
|
4 Manufacturing Techniques for Nanoparticulate Drug-Delivery Systems |
|
|
300 | (1) |
|
4.1 Interfacial Polymerization of Alkylcyanoacrylate Monomers |
|
|
300 | (1) |
|
4.2 Interfacial Deposition of Performed Polymers |
|
|
301 | (1) |
|
5 Nanoparticulate Drug Delivery System Applications |
|
|
301 | (8) |
|
5.1 Nanoparticulate System for Cancer |
|
|
301 | (1) |
|
5.2 Ocular Applications of Nanoparticulate Drug Delivery System |
|
|
302 | (1) |
|
5.3 Nanoparticulate System for Central Nervous System |
|
|
303 | (1) |
|
5.4 Nanomaterials as Gene Therapy |
|
|
304 | (4) |
|
5.5 Nanomaterials for Treatment of Vascular Thrombosis |
|
|
308 | (1) |
|
6 Nanomaterials as Targeted Delivery |
|
|
309 | (8) |
|
|
309 | (2) |
|
6.2 Nanomaterials as Proteins and Peptides |
|
|
311 | (3) |
|
|
314 | (1) |
|
6.4 Nanomaterials as Enzymes for Drug Delivery |
|
|
315 | (1) |
|
6.5 Nanomaterials as Mucoadhesives |
|
|
316 | (1) |
|
|
317 | (1) |
|
|
318 | (9) |
|
|
318 | (9) |
|
Chapter 12 Antiviral and Antimicrobial (Antibacterial) Potentiality of Nano Drugs |
|
|
327 | (16) |
|
|
|
|
|
1 Nanoparticles as Promising Research |
|
|
328 | (1) |
|
|
329 | (3) |
|
|
329 | (2) |
|
|
331 | (1) |
|
|
332 | (3) |
|
3.1 Polymeric Nanoparticles |
|
|
332 | (1) |
|
3.2 Solid Lipid Nanoparticles |
|
|
333 | (1) |
|
|
334 | (1) |
|
|
335 | (1) |
|
|
335 | (1) |
|
|
336 | (1) |
|
|
337 | (1) |
|
|
337 | (6) |
|
|
337 | (6) |
|
Chapter 13 Antiviral and Antimicrobial Potentiality of Nano Drugs |
|
|
343 | (14) |
|
|
|
|
|
|
343 | (1) |
|
2 Antimicrobial Activity of Carbon-Based Nanoparticles |
|
|
344 | (1) |
|
2.1 Carbon Nanotube Nanoparticles |
|
|
344 | (1) |
|
2.2 Fullerene Nanoparticles |
|
|
344 | (1) |
|
2.3 Graphene Oxide Nanoparticles |
|
|
345 | (1) |
|
3 Antimicrobial Activity of Metallic Nanoparticles |
|
|
345 | (3) |
|
|
346 | (1) |
|
3.2 Zinc Oxide Nanoparticles |
|
|
346 | (1) |
|
3.3 Aluminium Oxide Nanoparticles |
|
|
347 | (1) |
|
4 Polymeric Chitosan Nanoparticles |
|
|
348 | (1) |
|
5 Antiviral Property of Some Metallic Nanoparticles |
|
|
349 | (1) |
|
|
350 | (7) |
|
|
350 | (6) |
|
|
356 | (1) |
|
Chapter 14 Nanotechnology in Targeted Drug Delivery and Therapeutics |
|
|
357 | (54) |
|
|
|
|
|
|
357 | (1) |
|
|
358 | (11) |
|
|
358 | (4) |
|
2.2 Polymeric Nanocarriers |
|
|
362 | (1) |
|
|
362 | (1) |
|
|
363 | (1) |
|
|
363 | (1) |
|
2.6 Metallic Nanocarriers |
|
|
364 | (1) |
|
|
365 | (1) |
|
2.8 Ceramic-Based Nanocarriers |
|
|
366 | (1) |
|
2.9 Carbon-Based Nanocarriers |
|
|
366 | (1) |
|
|
367 | (1) |
|
2.11 Virus-Based Nanocarriers |
|
|
368 | (1) |
|
|
369 | (16) |
|
|
370 | (2) |
|
|
372 | (8) |
|
3.3 Moieties Conjugation Strategies |
|
|
380 | (5) |
|
|
385 | (26) |
|
|
385 | (2) |
|
|
387 | (1) |
|
|
387 | (24) |
|
Chapter 15 Engineering Nanomaterials for Smart Drug Release: Recent Advances and Challenges |
|
|
411 | (40) |
|
|
|
|
|
|
|
411 | (4) |
|
2 Engineering Nano Drug Systems |
|
|
415 | (1) |
|
3 Engineered Nanomaterials for Smart Drug Delivery |
|
|
415 | (3) |
|
4 Reports on Nanomaterials for Smart Drug Delivery |
|
|
418 | (15) |
|
|
418 | (1) |
|
|
419 | (1) |
|
|
420 | (1) |
|
4.4 Dendrimers and Hyperbranched Polymers |
|
|
420 | (2) |
|
4.5 Chitosan and Lecithin |
|
|
422 | (1) |
|
4.6 Liposomes and Niosomes |
|
|
423 | (2) |
|
|
425 | (1) |
|
4.8 Solid Lipid Nanoparticles |
|
|
426 | (1) |
|
4.9 Nanostructured Lipid Carriers |
|
|
426 | (1) |
|
|
426 | (1) |
|
|
427 | (1) |
|
4.12 Protein Albumin Nanoparticles |
|
|
428 | (1) |
|
|
428 | (1) |
|
4.14 Magnetic Nanoparticles |
|
|
429 | (1) |
|
4.15 Ceramic Nanoparticles |
|
|
429 | (1) |
|
|
429 | (1) |
|
4.17 Aptamer-Nanoparticle Conjugates |
|
|
430 | (1) |
|
4.18 Nanosuspensions and Nanocrystals |
|
|
431 | (1) |
|
4.19 Carbon Nanostructures |
|
|
432 | (1) |
|
5 Toxicity of Engineered Nanoparticles |
|
|
433 | (1) |
|
6 In Authors Laboratory: A Case Study of Nano Drug Formulation of Amphotericin B Against Leishmaniasis |
|
|
433 | (4) |
|
6.1 Synthesis and Characterization of Nano-Amphotericin B |
|
|
434 | (1) |
|
6.2 Anti-Ieishmanial Activity of Conventional- and Nano-AB |
|
|
435 | (2) |
|
7 Conclusions and Future Prospects |
|
|
437 | (14) |
|
|
438 | (13) |
|
Chapter 16 Nano Drugs for Curing Malaria: The Plausibility |
|
|
451 | (18) |
|
|
|
|
|
|
451 | (1) |
|
2 Life Cycle of the Malaria Parasite |
|
|
452 | (1) |
|
3 Conventional Malaria Chemotherapy |
|
|
452 | (3) |
|
4 Drug Targeting and Delivery |
|
|
455 | (1) |
|
4.1 Nano Drug Targeting in Malaria Treatment |
|
|
455 | (1) |
|
|
456 | (5) |
|
|
457 | (1) |
|
5.2 Solid Lipid Nanoparticles |
|
|
458 | (1) |
|
5.3 Polymeric Nanoparticles |
|
|
459 | (1) |
|
|
459 | (1) |
|
5.5 Metallic Nanoparticles |
|
|
460 | (1) |
|
|
460 | (1) |
|
5.7 Self-Assembling Protein Nanoparticles |
|
|
461 | (1) |
|
|
461 | (8) |
|
|
461 | (1) |
|
|
462 | (7) |
|
Chapter 17 Nanoparticles Mediated Gene Knockout Through miRNA Replacement: Recent Progress and Challenges |
|
|
469 | (30) |
|
|
|
|
|
469 | (2) |
|
2 Central Dogma of Molecular Biology and Regulation of Gene Expression |
|
|
471 | (4) |
|
2.1 Gene Knockout Strategies |
|
|
472 | (1) |
|
2.2 miRNA as a Tool for Regulation of Gene Expression |
|
|
473 | (1) |
|
2.3 miRNA Replacement Therapy |
|
|
474 | (1) |
|
3 Types of Nanoparticles Used in miRNA Replacement Therapy |
|
|
475 | (12) |
|
3.1 Polymer-Based Nanocarriers |
|
|
475 | (4) |
|
3.2 Lipid-Based Nanocarriers |
|
|
479 | (3) |
|
3.3 Metal/Meta-oxide Nanocarriers |
|
|
482 | (3) |
|
3.4 Other Nucleic Acid/Protein Based Nanocarriers |
|
|
485 | (2) |
|
4 Immunological Response Against Nanocarriers and miRNA |
|
|
487 | (1) |
|
5 Challenges of Nanocarriers-Based Delivery of miRNA |
|
|
488 | (1) |
|
6 Conclusions and Future Prospects |
|
|
489 | (10) |
|
|
489 | (8) |
|
|
497 | (2) |
|
Chapter 18 Transdermal and Intravenous Nano Drug Delivery Systems: Present and Future |
|
|
499 | (52) |
|
|
|
499 | (1) |
|
|
500 | (1) |
|
2.1 Why and When Is TDDS Important? |
|
|
500 | (1) |
|
3 Route of Drug Absorption: Skin |
|
|
500 | (5) |
|
3.1 Factors Influencing Nano Drug Transdermal Delivery |
|
|
503 | (2) |
|
4 Skin Permeation Enhancement |
|
|
505 | (12) |
|
4.1 Physical Penetration Enhancement |
|
|
505 | (1) |
|
4.2 Structure-Based Permeation Enhancement |
|
|
506 | (2) |
|
4.3 Electrical-Based Permeation Enhancement |
|
|
508 | (9) |
|
4.4 Velocity-Based Permeation Enhancement |
|
|
517 | (1) |
|
5 IrUravenous Route of Drug Administration |
|
|
517 | (2) |
|
5.1 Nanoparticles Toxicity: Intravenous Route of Drug Administration |
|
|
518 | (1) |
|
6 Nanocarriers for Transdermal and Intravenous Application |
|
|
519 | (14) |
|
6.1 Metallic Nanoparticles |
|
|
520 | (2) |
|
|
522 | (5) |
|
|
527 | (3) |
|
6.4 Polymeric Nanoparticles |
|
|
530 | (1) |
|
|
531 | (1) |
|
|
531 | (2) |
|
|
533 | (18) |
|
|
535 | (15) |
|
|
550 | (1) |
|
Chapter 19 Nanobased Intravenous and Transdermal Drug Delivery Systems |
|
|
551 | (44) |
|
|
|
|
|
551 | (2) |
|
2 Different Kinds of Constituents of Nano Drug Delivery Systems |
|
|
553 | (2) |
|
2.1 Inorganic Constituents |
|
|
553 | (1) |
|
|
554 | (1) |
|
|
554 | (1) |
|
|
555 | (1) |
|
|
555 | (9) |
|
|
555 | (2) |
|
|
557 | (1) |
|
|
558 | (1) |
|
|
559 | (2) |
|
|
561 | (2) |
|
|
563 | (1) |
|
5 Nano Transdermal Drug Delivery Systems |
|
|
564 | (10) |
|
|
565 | (1) |
|
|
566 | (2) |
|
|
568 | (3) |
|
|
571 | (1) |
|
|
572 | (1) |
|
|
573 | (1) |
|
6 Methods of Preparation of Nano DDS |
|
|
574 | (9) |
|
|
574 | (8) |
|
|
582 | (1) |
|
|
582 | (1) |
|
|
583 | (1) |
|
|
583 | (1) |
|
|
584 | (11) |
|
|
585 | (1) |
|
|
585 | (10) |
|
Chapter 20 Electrospun Nanofibers for Drug Delivery in Regenerative Medicine |
|
|
595 | (32) |
|
|
|
|
|
|
|
|
595 | (2) |
|
2 Methods for Loading Drugs/Biomolecules Through Electrospinning |
|
|
597 | (2) |
|
|
599 | (1) |
|
|
600 | (1) |
|
5 Stimuli-Responsive Polymers in Drug Delivery |
|
|
601 | (1) |
|
6 Drug Release Using Electrospun Fibers |
|
|
602 | (8) |
|
6.1 Delivery of Antibiotics |
|
|
603 | (3) |
|
6.2 Delivery of Antiinflammatory Drugs |
|
|
606 | (1) |
|
6.3 Delivery of Antiretroviral Drugs |
|
|
606 | (1) |
|
6.4 Delivery of Anticancer Drags |
|
|
607 | (2) |
|
6.5 Delivery of Other Drugs |
|
|
609 | (1) |
|
7 Biomolecules and Drug Delivery for Regenerative Tissue Engineering |
|
|
610 | (7) |
|
7.1 Wound Tissue Engineering |
|
|
610 | (1) |
|
7.2 Bone Regenerative Tissue Engineering |
|
|
611 | (2) |
|
7.3 Neural Regenerative Tissue Engineering |
|
|
613 | (2) |
|
7.4 Heart and Vascular Tissue Engineering |
|
|
615 | (1) |
|
7.5 Other Tissue Engineering Applications of Drug/Biomolecule-Loaded ESM |
|
|
616 | (1) |
|
8 Conclusion and Future Perspective |
|
|
617 | (10) |
|
|
617 | (1) |
|
|
618 | (9) |
Index |
|
627 | |